ADAR1 Capital Management LLC Cuts Stock Position in KALA BIO, Inc. (NASDAQ:KALA)

Posted by Chris Copeland on Apr 7th, 2025

ADAR1 Capital Management LLC trimmed its position in shares of KALA BIO, Inc. (NASDAQ:KALA – Free Report) by 28.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 220,373 shares of the company’s stock after selling 85,694 shares during the quarter. ADAR1 Capital Management LLC owned approximately 3.62% of KALA BIO worth $1,529,000 as of its most recent filing with the SEC.

Separately, Geode Capital Management LLC boosted its holdings in shares of KALA BIO by 28.4% during the 4th quarter. Geode Capital Management LLC now owns 47,642 shares of the company’s stock worth $331,000 after purchasing an additional 10,526 shares during the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of KALA BIO in a research report on Friday.

View Our Latest Analysis on KALA BIO

KALA BIO Price Performance

Shares of NASDAQ KALA opened at $4.24 on Monday. KALA BIO, Inc. has a 1-year low of $4.01 and a 1-year high of $11.20. The company has a market cap of $25.83 million, a price-to-earnings ratio of -0.34 and a beta of -1.70. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. The stock’s 50-day moving average is $7.42 and its two-hundred day moving average is $6.78.

KALA BIO (NASDAQ:KALA – Get Free Report) last released its quarterly earnings data on Friday, March 28th. The company reported ($1.74) EPS for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.54. Analysts forecast that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

About KALA BIO

(Free Report)

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.